Metastatic breast cancer: what still needs to be (re)considered?

#BreastCancer #mBC #2025Guidelines #AGO  


Metastatic breast cancer (mBC) remains one of the leading causes of cancer-related death among women. Despite significant therapeutic advances over the past two decades, it is still considered incurable, with frequent relapses and time-limited responses to treatment. Major challenges in clinical practice include the molecular heterogeneity of tumors, secondary resistance to targeted therapies, the management of complex metastatic sites (bone, brain, visceral), and the lack of unified guidelines for certain rare molecular profiles or patients progressing after CDK4/6 inhibition.